Dear Mr. Siri:

This letter is our final response to your Centers for Disease Control and Prevention and Agency for Toxic Substances and Disease Registry (CDC/ATSDR) Freedom of Information Act (FOIA) request of March 17, 2023, assigned #23-00898-FOIA, for (see attached request).

The records used to support the safety of vaccine coadministration referenced in the tweet are:

From the publicly available White House video: https://files.hiv.gov/s3fs-public/2022-12/HHS_OIDP_MonkeypoxFAQs_DemetreDaskalakis_Q13.mp4

From CDCs publicly available website: JYNNEOS Vaccine website
https://www.cdc.gov/poxvirus/mpox/interim-considerations/jynneos-vaccine.html#coadministration

Currently, there are no data on administering JYNNEOS vaccine at the same time as other vaccines. Because JYNNEOS is based on a live, attenuated non-replicating orthopoxvirus, JYNNEOS typically may be administered without regard to timing of most other vaccines. This includes simultaneous administration of JYNNEOS and other vaccines, including influenza vaccine, on the same day, but at different anatomic sites if possible. There are special considerations if administering the COVID-19 vaccine. See the Interim Clinical Considerations for Use of COVID-19 Vaccines (https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html), and best practices for multiple injections (https://www.cdc.gov/vaccines/hcp/administer-vaccines.html).

Overall, the information above was developed based upon recommendations from the Advisory Committee on Immunization Practices (ACIP). Specifically:

a. ACIP Smallpox and Monkeypox Vaccine Recommendations
(https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/smallpox.html)

b. ACIP Timing and Spacing Guidelines for Immunization (https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/spacing.html)

Additionally, a June 2022 MMWR describes ACIP recommendations "Use of JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) for Preexposure Vaccination of Persons at Risk for Occupational Exposure to Orthopoxviruses: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022" (https://www.cdc.gov/mmwr/volumes/71/wr/mm7122e1.htm)
Of note, the MMWR above states:

"Additional data on JYNNEOS vaccine are needed. Further studies are needed to determine the duration of protection after the 2-dose JYNNEOS vaccination series; recommendations regarding the frequency of booster doses can be modified accordingly. The effectiveness of a single dose JYNNEOS series should be evaluated if orthopoxvirus exposures occur before peak immunogenicity is achieved. Clinical trials evaluating the risk for myopericarditis and serious adverse events are needed to ensure that the risks are characterized and guidance about co-administration of JYNNEOS with mRNA COVID-19 vaccines can be elucidated."

If you need any further assistance or would like to discuss any aspect of the records provided please contact either our FOIA Requester Service Center at 770-488-6399 or our FOIA Public Liaison at 770-488-6246.

Sincerely,

Roger Andoh
CDC/ATSDR FOIA Officer
Office of the Chief Operating Officer
(770) 488-6399
Fax: (404) 235-1852

23-00898-FOIA